Marshall, Gerstein & Borun Expand Its Biotechnology Practice

March 18, 2015

Marshall, Gerstein & Borun LLP is pleased to announce the additions of partner Joshua T. Elliott, and biotech technical specialist Ben A. Hall.

Josh Elliott, formerly of Brinks Gilson & Lione, currently focuses his practice on patent law matters related to biochemistry and biotechnology, including advising and counseling clients on issues such as freedom-to-operate, infringement, validity, and design-around strategies. With over 15 years of intellectual property experience, Elliott has spent much of his career advising biotechnology/pharmaceutical companies on patent issues related to advancing products to market, including agricultural and biotherapeutic products. He received his B.S., with Distinction, in Chemistry (biochemistry track) from the University of North Carolina at Chapel Hill, where he was elected a member of Phi Beta Kappa, and his J.D., cum laude, from the University of Dayton School of Law, where he was a Loren M. Berry Scholar and a member of the University of Dayton Law Review.

Ben Hall, Ph.D., formerly a research professional at the University of Chicago, assists in prosecuting patent applications for clients as a technical specialist in a variety of industries, specifically related to biotechnology. His life science-based doctoral and postdoctoral training and multidisciplinary background provide extensive research experience and knowledge in a wide range of areas, including molecular biology, oncology, diabetes, biological diagnostic systems, and pharmacology. His industry experience includes working with two biotechnology startup companies and The University of Chicago Technology Transfer office. Dr. Hall received his B.S. with honors in pharmacology and Ph.D. in biomedical sciences from Newcastle University in the UK. Dr. Hall has authored several peer-reviewed research articles in the fields of oncology and diabetes.

“Marshall, Gerstein & Borun’s Biotechnology team is proud of its industry-leading work to protect the innovations of clients from Fortune 250 corporations to non-profits and in advising clients how to navigate through complex intellectual property webs,” said Heather Kissling, chair of the biotechnology group. “We’re confident that Josh and Ben will provide more unique value to our clients,” added Kissling. The firm's large biotechnology practice group includes lawyers, patent agents, and technical specialists experienced in a variety of technical disciplines, including DNA, RNA, protein, and antibody therapeutics; immunotherapy; diagnostics; plant biotechnology; industrial biotechnology and research platforms; nanotechnology; and interdisciplinary inventions. The team handles all variety of biotechnology IP matters, including patent litigation and prosecution; counseling; agreements and transactions; and pharmaceutical trademarks. The vast majority of team members have advanced scientific degrees or biotechnology industry, or research experience.